The cardiovascular (CV) risk in patients with diabetes is estimated to be two or three times higher than in the non-diabetic population. The prognosis of patients with diabetes following myocardial infarction (MI) remains poorer in comparison with non-diabetics. Besides traditional risk factors, some factors related to diabetes, including blood glucose control, are responsible for the acceleration of vascular disease.
The prognosis of patients with diabetes following MI can be markedly improved if coronary revascularisation is used when possible in nondiabetic patients. 15 Statin treatment should also be prescribed in diabetic patients with coronary disease and the Treating New Targets (TNT) study has shown that the cardiac prognosis is improved when LDL-C levels are reduced to 70mg/dl, instead of 100mg/dl. 16 A number of studies have shown that the prognosis post-MI is related to blood glucose levels. 17, 18 Experimental findings show in favour of the deleterious role of blood glucose on the arteries. 19 This highlights the importance of improving blood glucose in these patients. The Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) studies have confirmed that glycated haemoglobin (HbA1c) levels were significant and independent mortality predictors. The first DIGAMI trial supported the use of intensive insulin treatment after MI in patients with diabetes. 20 These results were not confirmed by the DIGAMI 2 trial, which improved the first study's protocol and included more patients. 21 The DIGAMI 2 trial suggests that type 2 diabetic patients should receive intensive glucose control after MI, but that this can be achieved by alternative, and possibly more convenient, treatments than insulin. Therefore, in practice, antidiabetic treatment after MI can consist of insulin or other hypoglycaemic agents. However, insulin treatment is often necessary due to poor or unstable glycaemic control, and to contraindications associated with some oral agents. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) trial tested pioglitazone in addition to conventional therapy in patients with type 2 diabetes and CV disease. All-cause mortality, non-fatal MI and stroke were reduced, but the incidence of heart failure was increased. 22 Therefore, glitazones may not be recommended for use during acute coronary syndromes.
In primary prevention, some trials suggest that blood glucose control may reduce CV risk. In the UKPDS, a 0.9% HbA 1c reduction was associated with a 16% reduction of MI incidence with a borderline significance. 23 In type 1 diabetes, the Epidemiology of Diabetes
Interventions and Complications (EDIC) extension of the Diabetes
Control and Complications Trial (DCCT) strongly endorses early
